You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
CONFERENCE REPORT
-
2025 ASCO:Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with Acquired MET Amplification or Overexpression after Failure on EGFR-TKI Treatment: A Phase Ib/II Study
Author:Caicu Zhou etc.
Time:2025-05-31
2025
05-31
View Details
-
2024 WCLC: Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
Author:Caicu Zhou etc.
Time:2024-09-10
2024
09-10
View Details